CD8 T cell-mediated depletion of HBV surface-antigen-expressing, bilineal-differentiated liver carcinoma cells generates highly aggressive escape variants

References

• Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (CHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2018;6:11–10. doi:10.2147/JHC.S159805.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi FR. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3.
   PubMed Web of Science ®Google Scholar
• Lee HW, Chan H-Y. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol. 2020;55(4):383–389. doi:10.1007/s00535-020-01665-z.
   PubMed Web of Science ®Google Scholar
• Flores JE, Thompson AJ, Ryan M, Howell J. The global impact of hepatitis b vaccination on hepatocellular carcinoma. Vaccines (Basel). 2022;10(5):793. doi:10.3390/vaccines10050793.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: defective surface antigen expression and pathogenesis. World J Gastroentero. 2018;24(31):3488–3499. doi:10.3748/wjg.v24.i31.3488.
   PubMed Web of Science ®Google Scholar
• Li YW, Yang FC, Lu HQ, Zhang JS. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroentero. 2016;22(6):1943–1952. doi:10.3748/wjg.v22.i6.1943.
   PubMed Web of Science ®Google Scholar
• Zhu D, Liu L, Yang D, Fu S, Bian Y, Sun Z, He J, Su L, Zhang L, Peng H, et al. Clearing persistent extracellular antigen of hepatitis B virus: an immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination. J Immunol. 2016;196(7):3079–3087. doi:10.4049/jimmunol.1502061.
   PubMed Web of Science ®Google Scholar
• Wu S, Ye S, Lin X, Chen Y, Zhang Y, Jing Z, Liu W, Chen W, Lin X, Lin X. Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling. Cancer Lett. 2021;499:175–187. doi:10.1016/j.canlet.2020.11.032.
   PubMed Web of Science ®Google Scholar
• Chen H, Mu M, Liu Q, Hu H, Tian C, Zhang G, Li Y, Yang F, Lin S. Hepatocyte endoplasmic reticulum stress inhibits hepatitis B virus secretion and delays intracellular hepatitis B virus clearance after entecavir treatment. Front Med. 2021;7:589040. doi:10.3389/fmed.2020.589040.
   Web of Science ®Google Scholar
• Kim SY, Kyaw YY, Cheong J. Functional interaction of endoplasmic reticulum stress and hepatitis B virus in the pathogenesis of liver diseases. World J Gastroentero. 2017;23(43):7657–7665. doi:10.3748/wjg.v23.i43.7657.
   PubMed Web of Science ®Google Scholar
• Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, Palmiter RD, Brinster RL. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A. 1987;84(19):6909–6913. doi:10.1073/pnas.84.19.6909.
   PubMed Web of Science ®Google Scholar
• Deng F, Xu G, Cheng Z, Huang Y, Ma C, Luo C, Yu C, Wang J, Xu X, Liu S, et al. Hepatitis B surface antigen suppresses the activation of nuclear factor kappa B pathway via interaction with the TAK1-TAB2 complex. Front Immunol. 2021;12:618196. doi:10.3389/fimmu.2021.618196.
   PubMed Web of Science ®Google Scholar
• Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Brinster RL, Palmiter RL, Palmiter RD. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell. 1989;59(6):1145–1156. doi:10.1016/0092-8674(89)90770-8.
   PubMed Web of Science ®Google Scholar
• Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus mutations leading to endoplasmic reticulum stress and their contribution to the progression of hepatocellular carcinoma. Int J Mol Sci. 2019;20(3):597. doi:10.3390/ijms20030597.
   PubMed Web of Science ®Google Scholar
• Li Y, Xia Y, Cheng X, Kleiner DE, Hewitt SM, Sproch J, Li T, Zhuang H, Liang TJ. Hepatitis B surface antigen activates unfolded protein response in forming ground glass hepatocytes of chronic hepatitis B. Viruses. 2019;11(4):386. doi:10.3390/v11040386.
   PubMed Web of Science ®Google Scholar
• Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Mathe YG, Laurent C, Laurent A, Bioulac-Sage P, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64(5):820–829. doi:10.1136/gutjnl-2013-306228.
   PubMed Web of Science ®Google Scholar
• Katz SF, Lechel A, Obenauf AC, Begus-Nahrmann Y, Kraus JM, Hoffmann EM, Duda J, Eshraghi P, Hartmann D, Liss B, et al. Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology. 2012;142(5):1229–39.e3. doi:10.1053/j.gastro.2012.02.009.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xin B, Yamamoto M, Goto M, Ooshio T, Kamikokura Y, Tanaka Hm Meng L, Mizukami Y, Okada Y, Mizukami Y, et al. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice. Cancer Sci. 2021;112(8):3111–3124. doi:10.1111/cas.14996.
   PubMed Web of Science ®Google Scholar
• Stifter K, Krieger J, Ruths L, Gout J, Mulaw M, Lechel A, Kleger A, Seufferlein T, Wagner M, Schirmbeck R. IFN-γ treatment protocol for MHC-I(lo)/PD-L1(+) pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential. J Immunother Cancer. 2020;8(2):e000692. doi:10.1136/jitc-2020-000692.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy S, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Otasek D, Morris JH, Bouças J, Pico AR, Demchak B. Cytoscape Automation: empowering workflow-based network analysis. Genome Biol. 2019;20(1):185. doi:10.1186/s13059-019-1758-4.
   PubMed Web of Science ®Google Scholar
• Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44–51. doi:10.1016/j.coi.2015.12.007.
   PubMed Web of Science ®Google Scholar
• Harms JS, Splitter GA. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther. 1995;6(10):1291–1297. doi:10.1089/hum.1995.6.10-1291.
   PubMed Web of Science ®Google Scholar
• Dhar GA, Saha S, Mitra P, Nag Chaudhuri R. DNA methylation and regulation of gene expression: guardian of our health. Nucleus. 2021;64(3):259–270. doi:10.1007/s13237-021-00367-y.
   Web of Science ®Google Scholar
• Qasim W, Brunetto M, Gehring AJ, Xue S-A, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol. 2015;62(2):486–491. doi:10.1016/j.jhep.2014.10.001.
   PubMed Web of Science ®Google Scholar
• Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. null. 2021;2(1):ltab026. doi:10.1093/immadv/ltab026.
   Google Scholar
• Kim CY, Tilles JG. Purification and biophysical characterization of hepatitis B Antigen. J Clin Invest. 1973;52(5):1176–1186. doi:10.1172/JCI107284.
   PubMed Web of Science ®Google Scholar
• Jiang M, Broering R, Trippler M, Poggenpohl L, Fiedler M, Gerken G, Lu M, Schlaak JF. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen. J Viral Hepat. 2014;21(12):860–872. doi:10.1111/jvh.12216.
   PubMed Web of Science ®Google Scholar
• Riedl P, Reiser M, Stifter K, Krieger J, Schirmbeck R. Differential presentation of endogenous and exogenous hepatitis B surface antigens influences priming of CD8(+) T cells in an epitope-specific manner. Eur J Immunol. 2014;44(7):1981–1991. doi:10.1002/eji.201343933.
   PubMed Web of Science ®Google Scholar
• Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73(2):409–422. doi:10.1016/j.jhep.2020.04.013.
   PubMed Web of Science ®Google Scholar
• Fumagalli V, Di Lucia P, Venzin V, Bono EB, Jordan R, Frey CR, Chisari FV, Guidotti LG, Iannacone M, Iannacone M. Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. J Exp Med. 2020;217(11):e20200298. doi:10.1084/jem.20200298.
   PubMed Web of Science ®Google Scholar
• Lee W-S, Lee K-W, Heo J-S, Kim S-J, Coi S-H, Kim Y-I, Joh J-W. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36(10):892–897. doi:10.1007/s00595-006-3276-8.
   PubMed Web of Science ®Google Scholar
• Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroen Hepatol. 1996;11(8):758–764. doi:10.1111/j.1440-1746.1996.tb00327.x.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009;101(15):1066–1082. doi:10.1093/jnci/djp180.
   PubMedGoogle Scholar
• Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45(5):1187–1192. doi:10.1002/hep.21612.
   PubMed Web of Science ®Google Scholar
• Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, Livingston SE. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010;51(5):1531–1537. doi:10.1002/hep.21612.
   PubMed Web of Science ®Google Scholar
• Moini M, Fung S. HBsAg loss as a treatment endpoint for chronic HBV infection: hBV cure. Viruses. 2022;14(4):657. doi:10.3390/v14040657.
   PubMed Web of Science ®Google Scholar